Sanofi, Bristol-Myers were fined 834 million USD for blood thinning drug scandal
Bristol-Myers Squibb (USA) and Sanofi (France) have just been fined 834 million USD for not properly warning about health risks for patients of color using blood thinning drugs Plavix.
|Hawaii accused Bristol-Myers and Sanofi of violating the state’s consumer protection laws by marketing Plavix without disclosing the drug could reduce or not work for some patients. Photo: AFP / VNA|
Reuters news agency quoted Dean Ochiai, a judge of the city of Honolulu – the capital of Hawaii state on February 15, that Bristol-Myers and Sanofi did unfair and fraudulent business between 1998 and 2010 through the do not change the Plavix label to warn doctors and patients, even though some potential risks are known.
Hawaii Attorney General Clare Connors – who sued Bristol-Myers and Sanofi in 2014, said the ruling “placed the pharmaceutical industry on warning that they would be held accountable for public deception and put profits above security. “
Bristol-Myers and Sanofi jointly produced the drug Plavix under a previous partnership agreement. In a recent joint statement, the two pharmaceutical companies said they would appeal on the grounds that the ruling “is not supported by law and contrary to the evidence in court”. These two pharmacies still believe that Plavix is safe and effective.
Before sanctioning Bristol-Myers and Sanofi each with $ 417 million each, Judge Ochiai presided over a four-week trial without a jury and was conducted online via the Zoom platform due to the effects of the Covid pandemic. -19.
Hawaii authorities have accused Bristol-Myers and Sanofi of violating state consumer protection laws by marketing Plavix without disclosing the drug may reduce or not work for some patients, especially those who of East Asian origin and Pacific Islands.
Plavix is prescribed to prevent stroke and heart attack. This blood-thinning drug needs to be activated by enzymes in the injected body itself, and these enzymes are genetically different.
Previous studies have shown that about 14% of Chinese patients are unable to properly metabolize Plavix, compared to 4% in black patients and 2% in Caucasian patients.
In 2010, the US Food and Drug Administration issued a new warning label on the drug Plavix to reflect the above information.
Bristol-Myers and Sanofi are also facing similar lawsuits over the drug Plavix in the state of New Mexico.